Characterization of a Macaque Anti-Rh17-Like Monoclonal Antibody

Abstract

In order to produce macaque monoclonal antibodies (mAbs) against human red blood cell (RBC) antigens, macaques were immunized with human and gorilla RBCs and their spleen lymphocytes were fused with man-mouse heteromyeloma cells. One macaque-mouse heterohybridoma produced a macaque IgG* (Cyn2-4D5) which agglutinated all human RBCs but not rare human variants Dc–, D– –, and Rh_null. Thus, Cyn2-4D5 exhibited RH17-like reactivity. The specificity of Cyn2-4D5 for RHCE-encoded polypeptides was confirmed by specific immunoprecipitation of RhcE and RhCe polypeptides from human RBCs and the absence of immunoprecipitation of the RhD polypeptides extracted from D– – RBCs. This study demonstrates that it is possible to produce macaque mAbs against human RBC blood group antigens.

DIIIa and DIII Type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications

“…If fresh pretransfusion RBCs were available, samples were typed for hr B with the FOR-2E3 monoclonal antibody10 or polyclonal anti-hr B from our collections. Some were also tested with polyclonal anti-DAK, -V, -VS, and -V/VS from our collections.…”

Biocompatible coupling of therapeutic fusion proteins to human erythrocytes

“…Both antigens are present on RBCs from nearly 100% of the population and are considered erythroid specific. 35,36 Although targeting Wr b can induce rigidity, 28 ligands to RhCE determinants have not been extensively characterized on human RBCs with respect to effects on red cell physiology. These antibodies were fused to the extracellular domain of human TM (hTM-scFv) to produce a multifaceted thromboprophylactic agent.…”

Rh Haplotypes That Make e But Not hr^B Usually Make VS

“…The anti-hr B -like monoclonal antibody, FOR-2E3, has been described elsewhere [16]. Some human polyclonal reagents were gifts from colleagues: anti-hr B and anti-hr S from Elizabeth Smart, Natal Blood Transfusion Service, Durban, South Africa; anti-VS from Susan Wilkinson, University of Cincinnati, Ohio, USA, and anti-D made by a partial D, category III individual through the Serum, Cells and Rare Fluid (SCARF) exchange program.…”

“…Similarly, we found an excess of persons with r' S among patients who had formed anti-hr B . When a human monoclonal antibody with anti-hr B -like specificity became available [16] we were able to screen for the hr B -phenotype without preselection by Rh phenotype. We then tested hr B -samples for VS. We report here that among 65 e+, apparent hr B -samples, 59 (91%) were VS+.…”